Mometasona Furoato Stada (Mometasone Furoate Anhydrous)

Mometasone furoate binds to glucocorticoid receptors inside nasal mucosal cells, modulating gene transcription. This reduces the production of inflammatory cytokines, chemokines, and mediators, leading to decreased swelling, mucus formation, and vascular permeability in the nasal lining.

The prescribed dose of Mometasona Furoato Stada is determined by the treating clinician based on the patient’s age, severity of symptoms, and response to therapy. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with older agents such as beclomethasone or fluticasone, mometasone often provides comparable or superior symptom control with once‑daily dosing and minimal systemic absorption.

Store Mometasona Furoato Stada at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing the product.

The spray is administered intranasally. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The procedure is then repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, and hypersensitivity reactions such as rash or anaphylaxis. Patients should seek medical attention if they experience any of these events.

Individuals with a known hypersensitivity to mometasone furoate, other corticosteroids, or any component of the formulation should avoid this product. It is also contraindicated in patients with untreated fungal, viral, or bacterial infections of the nasal passages until the infection is resolved.